About Index Trending news
Top 50 Pricing

Clinical Trials

10–100 Companies


Funding and Acquisitions

2016 Q1

2 + 0
Curators of Clinical Trials

Chiltern Railways to test smartphone detection payment system

Seed fund

Healthcare Company Abreos Biosciences Raises Seed Funding Round

The Motley Fool

The $100 Million Platform Intrexon Investors Forgot

The Motley Fool

Why Intrexon Won't Commercialize Fuels by 2018

The Motley Fool

Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc.

The Motley Fool

Intrexon Battles Thermodynamics, but Thermodynamics Always Wins

The Motley Fool

Intrexon vs. MosquitoMate: Who Has the Better Zika Tool?

$23,000,000 Venture capital (Series B)
businesswire , FinSMEs

Omicia Raises $23 Million in Series B Funding | Business Wire

The Motley Fool

Here's Why Intrexon Corporation Was All the Buzz in May

The Motley Fool

Regulatory Obstacles and Opportunities Facing Intrexon's Natural-Gas-to-Fuels Platform

The Motley Fool

Why Intrexon and Dominion Resources Are Excited About Natural Gas-to-Fuels

$1,700,000 Venture capital (Series Undisclosed)
prnewswire , FinSMEs

Dallas-Based Bone Solutions, Inc. Receives $1.7 million in Funding

The Motley Fool

Intrexon's Risky Revenue Machine

The Motley Fool

Intrexon Delivers Revenue Growth (Again) While Avoiding Elephant in the Room

Earnings Stock markets
The Motley Fool

Intrexon Corporation Shares Were Stung in April -- Here's Why

The Motley Fool

Is Intrexon Really a House of Cards?

Stock markets Science
Product Hunt


The Motley Fool

What's Behind Intrexon's Steep Sell-Off Today

The Motley Fool

3 Things Needed to Make Intrexon's Zika Virus Cure a Success


Cofactor Genomics Acquires Narus Biotechnologies